ライフサイエンスコーパス: dopamine receptor

1 to the mushroom bodies, via the D5-like DAMB dopamine receptor.

2 re-based campaign for new agonists of the D4 dopamine receptor.

3 says and inhibition of ligand binding to the dopamine receptor.

4 y neurons expressing either the D1 or the D2 dopamine receptor.

5 brary contained 453,000 ligands for the D(4) dopamine receptor.

6 180-pM subtype-selective agonist of the D(4) dopamine receptor.

7 ium spiny neurons (MSNs) expressing D1 or D2 dopamine receptors.

8 mine ramps are an effective signal to occupy dopamine receptors.

9 ighting the functional role of extrastriatal dopamine receptors.

10 ir predominant expression of either D1 or D2 dopamine receptors.

11 ts through mechanisms not supported by other dopamine receptors.

12 ty during risky decision-making and striatal dopamine receptors.

13 that it was mediated by activation of D1/D5 dopamine receptors.

14 eptors: D1 and Invertebrate-specific D1-like dopamine receptors.

15 sal hippocampus despite the dense network of dopamine receptors.

16 ed preparations, suggesting spinally located dopamine receptors.

17 prepared from HEK293 cells expressing human dopamine receptors.

18 CZ) function primarily by blocking D(2)-type dopamine receptors.

19 ation (pERK) while lacking activity at other dopamine receptors.

20 lly expressed proteins, including D1- and D2-dopamine receptors.

21 ectively expressing either D1-dopamine or D2-dopamine receptors.

22 ing pathway involving multiple serotonin and dopamine receptors.

23 of striatal synapses expressing presynaptic dopamine receptors.

24 n requires a balance between the activity of dopamine receptor 1 (D1) and dopamine receptor 2 (D2).

25 mouse nAc and were located preferentially in dopamine receptor 1 (DRD1)-positive MSNs.

26 wed that Npas2 is preferentially enriched in dopamine receptor 1 containing medium spiny neurons (D1R

27 gneto to delineate a causal role of striatal dopamine receptor 1 neurons in mediating reward behavior

28 atory subunit 1B(+) BLA pyramidal neurons to dopamine receptor 1(+) CeA neurons define a pathway for

29 dopamine-induced surface GluA1 expression in dopamine receptor 1-expressing medium spiny neurons.

30 e of Neuron, O'Connor et al. (2015) identify dopamine receptor 1-expressing neurons that project to t

31 We found that one population, dopamine receptor 1-expressing neurons, act as a critica

32 allosteric modulator (NAM) of the D(2)-like dopamine receptors 1 was identified through virtual liga

33 ine levels (150 mg of levodopa) and blocking dopamine receptors (1.5 mg of haloperidol) in the contex

34 ng c-Fos induction and excitatory input onto dopamine receptor-1 (D1) containing NAc medium spiny neu

35 The ghrelin receptor (GHSR1a) and dopamine receptor-1 (DRD1) are coexpressed in hippocampa

36 P-expressing neurons in adult Area X express dopamine receptors 1A, 1B, and 2.

37 ntiation of excitatory transmission (LLP) on dopamine receptor 2 (D2)-MSNs.

38 us characterization of Slc6a15 as a striatal dopamine receptor 2 (D2)-neuron-enriched gene, we examin

39 the activity of dopamine receptor 1 (D1) and dopamine receptor 2 (D2).

40 We demonstrate that GBM cells express dopamine receptor 2 (DRD2), with elevated expression in

41 emale, deletion animals overexpress mRNA for dopamine receptor 2 and adenosine receptor 2a in the str

42 Activation of dopamine receptor 2 long (D2L) switches the signaling of

43 hile R-spondin 2(+) BLA pyramidal neurons to dopamine receptor 2(+) CeA neurons define a pathway for

44 , we show that ELS-induced downregulation of dopamine receptor 3 (Drd3) signaling and its correspondi

45 The D3 dopamine receptor, a member of the Gi-coupled D2 family

46 ceptors in PFC.SIGNIFICANCE STATEMENT The D3 dopamine receptor, a member of the Gi-coupled D2 family

47 The hypothesis that dopamine receptor activation enhances perceptual perform

48 Dopamine receptor activation is known to enhance both vi

49 direct link has not been established between dopamine receptor activation, NAc cue-evoked neuronal ac

50 of this cross-sensitization, potentially via dopamine receptor activation.

51 we uncover a specific mechanism by which D2 dopamine receptor activity modulates decision-making whe

52 Dopamine receptor activity modulates the coupling of the

53 acological manipulations of gap junction and dopamine receptor activity provide compelling evidence t

54 er dopaminergic modulation with a placebo, a dopamine receptor agonist bromocriptine or a dopamine re

55 ectroretinogram b-wave from cones, whereas a dopamine receptor agonist can potentiate the cone-driven

56 ioural responses after challenge with the D2-dopamine receptor agonist quinpirole.

57 xaggerated in DRD mice in response to the D1-dopamine receptor agonist SKF 81297.

58 drenoreceptor antagonist, timolol, the D1/D5 dopamine receptor agonist, SKF38393, and the H2 histamin

59 e-blinded, placebo-controlled study with the dopamine receptor agonists cabergoline (a D2 agonist) an

60 sor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonists reduced the number of histami

61 Administration of D1- or D2-like dopamine receptor agonists to enhance dopamine signallin

62 ceptive neurons, the effects of dopamine and dopamine receptor agonists were tested on the capsaicin-

63 hallenged with l-dopa (levodopa) and various dopamine receptor agonists, and resulting rotational beh

64 jor health problems in diabetic patients, D1 dopamine receptor agonists, which are already in clinica

65 and surveys the prospects for developing new dopamine receptor allosteric drugs with SB269652 as the

66 We found previously that loss of D2-family dopamine receptors ameliorated tauopathy in multiple mod

67 d a novel G protein-biased agonist of the D2 dopamine receptor and identified structural features tha

68 veral G-protein-coupled receptors, including dopamine receptor and mu opioid receptor (MOR).

69 The D2 dopamine receptor and the serotonin 5-hydroxytryptamine

70 Thus, it can be speculated that a failure of dopamine receptor and transporter homoeostasis might und

71 l advance has been made in Drosophila on the dopamine receptors and circuits mediating olfactory lear

72 Alterations of dopamine receptors and dopamine synthesis are seen in ag

73 -induced neurotoxicity, associations between dopamine receptors and gray-matter volume have been unex

74 ed an association between direct measures of dopamine receptors and neural representations of subject

75 s is consistent with the cellular actions of dopamine receptors and received support from optogenetic

76 n FFS evaluation of interactions between the dopamine receptors and the Gbetagamma complex.

77 , adrenergic receptors, adenosine receptors, dopamine receptor, and sphingosine 1-phosphate receptor.

78 hin the cortex and striatum, as well as with dopamine receptor- and calbindin-expressing cells within

79 Although dopamine receptor antagonism has long been associated wi

80 As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a

81 ent to which bilateral aDLS infusions of the dopamine receptor antagonist alpha-flupenthixol (0, 5, 1

82 dopamine receptor agonist bromocriptine or a dopamine receptor antagonist sulpiride (dopamine study n

83 r findings suggest that the combination of a dopamine receptor antagonist with radiation enhances the

84 ion, was attenuated by pretreatment with the dopamine receptor antagonist, flupenthixol, into the cor

85 oselective synthesis of (+)-sonepiprazole, a dopamine receptor antagonist.

86 ed" methamphetamine seeking, using selective dopamine receptor antagonists (SCH39166 or raclopride) a

87 ts, whereas administration of D1- or D2-like dopamine receptor antagonists to further reduce dopamine

88 Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypi

89 ion and depression-like symptoms, than other dopamine receptor antagonists.

90 nge alcohol drinking, and its sensitivity to dopamine receptor antagonists.

91 domisation was stratified by baseline use of dopamine receptor antagonists.

92 dopamine neuron stimulation and resistant to dopamine receptor antagonists.

93 ction neurons that express type-1 and type-2 dopamine receptors are dichotomous, such that these neur

94 Although D1 and D2 dopamine receptors are differentially expressed in the d

95 Dopamine receptors are implicated in the pathogenesis an

96 Here we demonstrate that dopamine receptors are present in sensory hair cells at

97 tor, a member of the Gi-coupled D2 family of dopamine receptors, are expressed throughout limbic circ

98 We identified the Drd3 dopamine receptor as a direct transcriptional target of

99 d by dopamine, and requires activation of D1-dopamine receptors, as well as NMDA receptors (NMDAR) an

100 ers are associated with deficits in striatal dopamine receptor availability, abnormalities in mesocor

101 D2 and D3 dopamine receptors belong to the largest family of cell

102 ine D5 receptor (D5R) is a Galpha(s)-coupled dopamine receptor belonging to the dopamine D1-like rece

103 vided mixed evidence regarding central D2/D3 dopamine receptor binding and its relationship with obes

104 Here we developed a neurochemical model of dopamine receptor binding taking into account the differ

105 he susceptibility of alcohol seeking to aDLS dopamine receptor blockade actually predicted the vulner

106 Dopamine receptor blockade did not prevent the MDPV-indu

107 Reversal learning was improved after dopamine receptor blockade in the nucleus accumbens; the

108 is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics.

109 To better understand how loss of D2-family dopamine receptors can ameliorate tau toxicity, we scree

110 atal glutamatergic synapses and of D1 and D2 dopamine receptor clusters.

111 (D1R decrease, D2R increase) in cell-surface dopamine receptor clusters.

112 nto how differential signaling downstream of dopamine receptors couples this timing to the dynamic re

113 lity of screening for distinct G proteins on dopamine receptor D(2) whose differential coupling to Ga

114 iny neuron (MSN) subtypes, those enriched in dopamine receptor D1 (D1-MSN) versus D2 (D2-MSN).

115 Applied to an endogenous dopamine receptor D1 (DRD1) agonist in the nucleus accum

116 Dopamine receptor D1 (DRD1) expression was also signific

117 mpounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited prolifera

118 ck-out mice, concomitant reduction of Gad65, dopamine receptor D1 (Drd1), and substance P expression

119 Dopamine receptor D1 modulates glutamatergic transmissio

120 iny neuron (MSN) subtypes, those enriched in dopamine receptor D1 versus dopamine receptor D2, in rew

121 e transporter, tyrosine hydroxylase, and the dopamine receptor D1, effects consistent with egocentric

122 s expressed either in dopamine neurons or in dopamine receptor D1-containing neurons play an importan

123 n hippocampal pyramidal neurons and striatal dopamine receptor D1-expressing neurons of Plcg1-deficie

124 As a proof-of-concept, we generated D1-dopamine receptor (D1) BAC MORF mice that label about 1%

125 nocked out (KO) in neurons expressing the D1 dopamine receptor (D1-KO), but not mice where WAVE1 was

126 m spiny projection neurons expressing the D1 dopamine receptor (D1-MSNs) in the nucleus accumbens.

127 beta2-adrenergic receptor (beta2-AR) and D1 dopamine receptor (D1-R).

128 often based on a distinction of two types of dopamine receptors, D1 and D2, with low and high affinit

129 ary glands is mediated through two different dopamine receptors, D1 and InvD1L, for different downstr

130 s involves autocrine dopamine activating two dopamine receptors: D1 and Invertebrate-specific D1-like

131 D1 and D2 dopamine receptors (D1DRs and D2DRs) may contribute diff

132 licated medial frontal neurons expressing D1 dopamine receptors (D1DRs) in temporal processing.

133 us work indicated that activation of D1-like dopamine receptors (D1DRs) in the nucleus accumbens shel

134 receptor (mGluRI) activation, facilitates D1 dopamine receptor (D1R) expression, and ensures long-ter

135 n the striatum and, by doing so, promotes D1 dopamine receptor (D1R) expression.

136 synergistically shaped by populations of D1 dopamine receptor (D1R)- and D2 dopamine receptor (D2R)-

137 ted by the differential actions of D1 and D2 dopamine receptors (D1R, D2R), the expression of which i

138 , respectively, with increased and decreased dopamine receptor D2 (DRD2) and serotonin receptor 2C (H

139 molecule close homolog of L1 (CHL1) and the dopamine receptor D2 (DRD2) are associated with psychiat

140 tein subunit alphai2 mediates the effects of dopamine receptor D2 (DRD2) on cyclic adenosine monophos

141 cholinergic muscarinic receptor 4 [Chrm4)], dopamine receptor D2 [Drd2], and transcription factor 4

142 An increased formation of dopamine receptor D2 homodimers has been suggested to be

143 The rs1076560 polymorphism of DRD2 (encoding dopamine receptor D2) is associated with alternative spl

144 activates this complex but does not inhibit dopamine receptor D2, a mediator of neurologic toxicity

145 clear whether any of these genes, other than dopamine receptor D2, are immediately relevant to antips

146 hose enriched in dopamine receptor D1 versus dopamine receptor D2, in reward and reinforcement leadin

147 triatopallidal projection neurons expressing dopamine receptor D2.

148 d regions with high expression levels of the dopamine receptors D2 and D3.

149 d regions with high expression levels of the dopamine receptors D2 and D3.SIGNIFICANCE STATEMENT Stud

150 was knocked out in neurons expressing the D2 dopamine receptor (D2-KO), exhibited a significant decre

151 ified a G protein-biased agonist of the D(2) dopamine receptor (D2R) that results in impaired beta-ar

152 ations of D1 dopamine receptor (D1R)- and D2 dopamine receptor (D2R)-expressing medium spiny neurons

153 ated whether individual differences in human dopamine receptors (D2R) were related to cognitive perfo

154 ychotic treatments, commonly antagonizing D2 dopamine receptors (D2Rs), on cognitive deficits and mem

155 Dopamine receptor D3 (DRD3) expressed on CD4(+) T cells

156 n is mediated primarily by activation of the dopamine receptor D3 subtype (DRD3), even though both DR

157 To identify novel D(3) dopamine receptor (D3R) agonists, we conducted a high-th

158 hat sub-threshold fear conditioning leads to dopamine receptor D4-dependent long-term depression (LTD

159 Dopamine receptors (DARs) are of particular interest for

160 aling type 4 (RGS4) activity, and blocked D1 dopamine receptor dependent long-term potentiation (LTP)

161 ls in adult mammals, that is required for D1 dopamine receptor-dependent ERK phosphorylation in mouse

162 lume signals in striatal target regions in a dopamine receptor-dependent manner.

163 This study investigated the dynamics of dopamine receptor desensitization and internalization, t

164 Additional loss of D2-family dopamine receptors did not synergize with bas-1 suppress

165 nnel in dopaminergic neurons and the D2-like dopamine receptor DOP-3.

166 ls innate immune responses through a D1-like dopamine receptor, DOP-4, in Caenorhabditis elegans.

167 Two dopamine receptors, DopR1 and DopR2, contribute to this

168 D offspring was associated with up-regulated dopamine receptor (DRD)-1 and -2 in the nucleus accumben

169 studied the role of nucleus accumbens (NAc) dopamine receptor (Drd)1- and Drd2-expressing neurons in

170 We demonstrate that D1 dopamine receptor (Drd1) signaling within the SCN is nec

171 psin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons,

172 D1 dopamine receptor (Drd1)-null mice are resistant to diet

173 and in vivo is caused by elevated levels of dopamine receptors (Drd1), which are expressed in motile

174 nzymes (COMT, DBH, DDC, MAOA, MAOB, and TH), dopamine receptors (DRD1, DRD2, DRD3, DRD4, and DRD5), t

175 g gene Dgcr8 results in the elevation of the dopamine receptor Drd2 in the auditory thalamus, an abno

176 The D2 dopamine receptor (DRD2) is a therapeutic target for Par

177 morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not signi

178 ated by antipsychotic agents that inhibit D2 dopamine receptors (Drd2s).

179 ances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant cli

180 lts were obtained for the 9-6 haplotype, the dopamine receptor DRD4 48 bp VNTR, and the enzyme COMT S

181 Dopamine signaled through a specific dopamine receptor (DRD4) to promote T helper 2 (Th2) cel

182 However, the role of extrastriatal dopamine receptors (DRs) in BG information processing is

183 at striatal neurons expressing the D1 and D2 dopamine receptors exert opposing brain-wide influences.

184 D2-dopamine receptors exhibited a change in the valence in

185 striatal region innervated, and the type of dopamine receptor expressed by striatal neurons.

186 pe and D2-type MSNs-based on the predominant dopamine receptor expressed.

187 esult of habitual intake of addictive drugs, dopamine receptors expressed in the brain are decreased,

188 we tested two major subtypes, Drd1 and Drd2 dopamine receptor expressing pyramidal neurons and found

189 port that, in dopamine-depleted mice, (1) D2 dopamine receptor expressing striatal projection neurons

190 Distinct populations of D1- and D2-dopamine receptor-expressing medium spiny neurons (D1-/D

191 ctivity-dependent gene Fos in both D1 and D2 dopamine receptor-expressing medium spiny neurons (MSNs)

192 Finally, D1 and D2 dopamine receptor-expressing medium spiny neurons (MSNs)

193 fferential projection patterns of D1- and D2 dopamine receptor-expressing MSNs.

194 eeking.SIGNIFICANCE STATEMENT Activity in D1 dopamine receptor-expressing neurons in the NAc is requi

195 It is widely accepted that D1 dopamine receptor-expressing striatal neurons convey the

196 to identify and interrupt the activity of D2 dopamine receptor-expressing striatal projection neurons

197 ic afferents to the striatum; and one of two dopamine-receptor-expressing efferent pathways of the st

198 frequency bands, we compared the D1- and D2-dopamine-receptor-expressing striatal medium spiny neuro

199 tein, NPAS2, in the NAc in the regulation of dopamine receptor expression and drug reward.

200 related behaviors that is dependent on their dopamine receptor expression.

201 all impaired dopamine-facilitated LTP or D1-dopamine receptor-facilitated LTP.

202 vealing a pathway by which drugs that target dopamine receptors for the treatment of neuropsychiatric

203 Depleting Rab23 prevents dopamine receptors from accessing the ciliary membrane.

204 Pharmacological enhancement of prefrontal D1 dopamine receptor function remains a promising therapeut

205 into a single signaling pathway: Dopamine--> Dopamine Receptor--> Scribble--> Rac--> Cofilin.

206 d GPCRs (e.g., the 5-HT(6) serotonin and D1R dopamine receptor) had reduced ability to generate cAMP

207 Drugs acting at D3 dopamine receptors have been suggested as medications fo

208 Against the D(4) dopamine receptor, hit rates fell almost monotonically w

209 The spinal cord also expresses all dopamine receptors; however, how the specific receptors

210 , we determined crystal structures of the D4 dopamine receptor in its inactive state bound to the ant

211 Chemical ablation of dopamine receptors in explant culture with the neurotoxi

212 opamine-targeting drugs and brain imaging of dopamine receptors in patients with mental illnesses.

213 , when combined with activation of D1 and D2 dopamine receptors in the contralateral (but not ipsilat

214 level, transient formation of homodimers of dopamine receptors in the membrane of stably transfected

215 Antagonizing dopamine receptors in the VLS blocked the stress-induced

216 neurons release dopamine, activation of the dopamine receptors increases the activity of these mecha

217 Despite evidence suggesting that midbrain dopamine receptors influence amphetamine-induced dopamin

218 e describe the invertebrate-specific D1-like dopamine receptor (InvD1L), which is highly expressed in

219 (PDF), and the invertebrate-specific D1-like dopamine receptor (InvD1L), with acinar cells.

220 in the wound beds, depending on the type of dopamine receptor involved.

221 tor, a member of the Gi-coupled D2 family of dopamine receptors, is expressed throughout limbic circu

222 However, this view assumes that dopamine receptor kinetics are instantaneous so that the

223 sing selective pharmacological compounds and dopamine receptor knockout (KO) mice, we show that DHCB

224 eceptor were increased in Het mice, while D1 dopamine receptor level was decreased.

225 damide, and dopaminergic system, measured by dopamine receptor levels and mRNA.

226 Increased DAT and D1 dopamine receptor levels appear to be responsible for th

227 as associated with the relative somatostatin/dopamine-receptors levels, especially sst5 and sst5TMD4.

228 Many subtype-selective dopamine receptor ligands developed for the D(2)-D(4) fa

229 The evaluation of a novel group of dopamine receptor ligands now showed that highly subtype

230 athways might tightly interact downstream to dopamine receptors, likely resulting over time to increa

231 This observation suggests that dopamine receptors may be activated in breast cancers, a

232 reduced, suggesting that activation of D1/D5 dopamine receptors may be preferentially linked to CaMKI

233 led information on the mechanisms underlying dopamine receptor-mediated modulation of brain reward ci

234 , decreased dopamine release, and smaller D2 dopamine receptor-mediated outward currents.

235 vestigated the presence of GlyRs in accumbal dopamine receptor medium spiny neurons (MSNs) of C57BL/6

236 he negative modulator SB269652 and D2 and D3 dopamine receptor monomers and dimers, and surveys the p

237 lateral striatum and critically implicate D1-dopamine receptor, NMDAR, Cdk5, and CaMKII in cortico-st

238 l dopamine signals translate into changes in dopamine receptor occupation in the striatum, and explai

239 amine from melanocytes activates the D1-like dopamine receptor on primary sensory neurons.

240 ttenuated by coadministration of either a D1 dopamine receptor or NMDA glutamate receptor antagonist.

241 c appendage led to a series of high-affinity dopamine receptor partial agonists.

242 opamine signals, we found that the D1 and D2 dopamine receptor populations responded very similarly t

243 irst time demonstrate that stimulation of D1 dopamine receptors present in dermal fibroblasts restore

244 individuals with changes in available D2/D3 dopamine receptors (presumably due to intrasynaptic dopa

245 e dopaminergic transmission through blocking dopamine receptors, primarily DRD2.

246 Activation of postsynaptic D1 dopamine receptors promoted the generation of long-lasti

247 the saccharin-exposed fathers, especially at dopamine receptor promoter regions, suggesting that epig

248 Here, we combine dopamine receptor reporter lines, anatomical tracing tec

249 protein-coupled receptors (GPCRs), including dopamine receptors, represent a group of important pharm

250 sted for interactions with AmpC and the D(4) dopamine receptor, respectively.

251 de, the latter to strengthen inference about dopamine receptor selectivity of methylphenidate's effec

252 evolutionary coupling potential derived from dopamine receptor sequences rather than with broader set

253 ase via D2-dependent synaptic plasticity and dopamine-receptor signal transduction.

254 imary screen were examined for orthogonal D2 dopamine receptor signaling activities including cAMP mo

255 Our results reveal how dopamine-receptor signaling pathways can detect the orde

256 ate- and GABA-receptor signaling, and not on dopamine-receptor signaling.

257 Ventral striatum- or D1 dopamine receptor-specific conditional knockout of Cdk5,

258 In the current study, we use dopamine receptor-specific pharmacology and multivoxel p

259 ppa opioid receptor (KOR), mu opioid, and D2 dopamine receptors stimulates peroxiredoxin 6 (PRDX6)-me

260 To illuminate dopamine receptor structure, function, and ligand recogn

261 ptor subtype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynapti

262 pressing tdTomato driven by the promoter for dopamine receptor subtype 1 (D1).

263 Triple transfections of the dopamine receptor subtype and Gbeta and Ggamma subunits,

264 investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid recepto

265 human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R).

266 en gray-matter thickness and BPnd for either dopamine receptor subtype in the control group.

267 previous studies neither isolated a role of dopamine receptor subtype nor identified the site of its

268 The five dopamine receptor subtypes (D(1-5)) are activated by the

269 tigated the dynamic interactions between the dopamine receptor subtypes and their G-proteins using tw

270 ed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might

271 arious types of mPFC neurons express several dopamine receptor subtypes, previous studies neither iso

272 ll-type specific role of GluN2B, GluN2A, and dopamine receptor subunits in the actions of NMDAR PAM v

273 Dopamine receptors thus reveal a previously unrecognized

274 m spiny neurons (MSN), expressing either the dopamine receptor type 1 (D(1) -R MSN) and forming the d

275 at large mushroom spines of MSNs expressing dopamine receptor type 1 (D1-MSNs).

276 f spiny projection neurons (SPNs) expressing dopamine receptor type 1 (D1-SPNs) or 2 (D2-SPNs) in mic

277 increases Gadd45b mRNA expression through a dopamine receptor type 1 (DRD1)-dependent mechanism.

278 g the direct, movement-promoting pathway, or dopamine receptor type 2 (D(2) -R MSN), forming the indi

279 ted in the etiology of SZ and coding for the dopamine receptor type 2 (D2).

280 larger synaptic responses in MSNs expressing dopamine receptor type 2 (D2-MSNs).

281 s and alpha2A-adrenergic receptor, GABAB, or dopamine receptor type 2 receptors did not reveal any in

282 e early stages of Huntington's disease, when dopamine receptor type 2-expressing striatal medium spin

283 BAB, cannabinoid receptor type 1 (CB1R), and dopamine receptor type 2.

284 This activity occurred within dopamine receptor type-2 (D2R)-expressing cells in the n

285 release, cell firing, and identification of dopamine receptor type.

286 pending on spike timing, dopamine level, and dopamine receptor type.

287 : neurotransmitter release, cell firing, and dopamine-receptor type.

288 The different affinity of striatal D1 and D2 dopamine receptor types has been argued to constrain the

289 dative stress and altered mRNA expression of dopamine receptors, tyrosine hydroxylase, and dopamine t

290 of leptin expression, glial activation, and dopamine receptor upregulation in the nucleus accumbens

291 This action of D1 dopamine receptors was mediated through the protein kina

292 nteract with the orthosteric binding site of dopamine receptors, was actually a negative allosteric m

293 rotein levels of dopamine transporter and D2 dopamine receptor were increased in Het mice, while D1 d

294 inst AmpC beta-lactamase (AmpC) and the D(4) dopamine receptor were simulated.

295 Song reinforcement diminished when dopamine receptors were blocked.

296 ructures of the A(2A) adenosine and the D(4) dopamine receptors were carried out, and 53 top-ranked m

297 Further, D1-dopamine receptors were supersensitive; adenylate cyclas

298 ctional design can also be found at level of dopamine receptors, where augmenting D1 and abating D2 r

299 y was performed to examine colocalization of dopamine receptors with endocrine hormones in HC and T1D

300 dence of robust alterations in glutamate and dopamine receptors within brain regions that are known t